BioAxone is poised to revolutionize the way spinal cord injury is treated. The company is currently privately financed and has grown a strong pipeline from licensing revenue and non-dilutive grant financing.

BioAxone is building on the following value:

  • Experienced management
  • Well balanced development team
  • Validated science
  • Over 14 issued patents (US and Global)
  • Key partnerships to build the business
  • Understanding of translational medicine to bring new drugs forward to clinical testing
  • Successful NIH/SBIR funding and a strong pipeline


For direct information on investment opportunities, please contact:

Dr. Lisa McKerracher
Chief Executive Officer, BioAxone
(617) 401 3115